Patent intelligence · US
US 7629005
Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
Pharmaceutical formulation consisting of a plant dry extract with a calcium coating
Patent details — US 7629005
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2009
- Expiration
- Dec 3, 2029
- Applicant
- Bionorica AG
- Claims
- 5
- CPC classes
- A61K, A61K36/185, A61K36/42, A61K36/48
Quick answer
US 7629005 (Pharmaceutical formulation consisting of a plant dry extract with a calcium coating) is held by Bionorica AG. Status: granted. Granted Dec 8, 2009. Expires Dec 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Bionorica AG
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K36/185, A61K36/42, A61K36/48, A61K36/71, A61K36/736
More from Bionorica AG
Related pharmaceutical patents in our USPTO index.
-
US 12312339
Polo like kinase 4 inhibitors
granted -
US 12239729
TRPV3 agonists for the treatment of skin conditions
granted -
US 12054556
Anti-PD-L1 antibody and use thereof
granted -
US 12018043
CD73 inhibitors
granted -
US 12005080
Method for promoting proliferation of immune cells
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11858915
Polo like kinase 4 inhibitors
granted -
US 11807658
CD73 inhibitors
granted
Frequently asked questions
What is US patent 7629005?
US 7629005 (Pharmaceutical formulation consisting of a plant dry extract with a calcium coating) is held by Bionorica AG. Status: granted. Granted Dec 8, 2009. Expires Dec 3, 2029 (3 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7629005?
Bionorica AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 52 pharmaceutical patents for this assignee.
When does US 7629005 expire?
Our index shows an expiration date of Dec 3, 2029 (3 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.